Navigation Links
i. Series Platelet Agitator PF15i

Productsi. Series Platelet Agitator PF15i
Company Helmer, Inc.
Item i. Series Platelet Agitator PF15i
Features 
  • Heavy-duty ball bearing gear motor.
  • Internal fan.
  • Delrin rollers and glides allow the drawer storage platform to agitate smoothly.
  • Sturdy, one piece perforated drawers for uniform air circulation.
Description Helmer platelet agitators offer a wide range of storage capacities. Delrin rollers and glides allow the drawer storage platform to agitate smoothly, eliminating the need for ball bearings which wear down and squeak. Sturdy, one-piece perforated drawers with non-slip textured coating provide uniform air circulation for your platelets.

i.Series platelet agitators feature a built-in motion alarm with adjustable volume. An alarm will sound when the side- to-side motion is not detected. When placed in an i.Series incubator, the agitator can be monitored by the i.Center with the AgiTrak system.

Info Helmer, Inc.
Customer Service: (800) 743-5637
Web site: http://www.helmerinc.com

Related medicine products :

1. Series 20000 Legacy
2. Series 24 Watt Sealed CO2 OEM Lasers
3. M/MK Series
4. EA/EKA Series
5. EHS Series
6. MLS-Series Top-Loading Autoclaves
7. Blood Coagulation Analyzer CG Series
8. Cytomics FC 500 Series
9. Series 400 Aggregometers
10. Series 500 Aggregometers
11. Series 490 Low Cost Automatic Optical Aggregometers
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products:
(Date:11/21/2008)... preterm labor , , FRIDAY, Nov. 21 (Heal...witch that activates the uterine muscles for contr...to therapies for preterm labor. , The molecule... surface of these uterine muscle cells, keeping th... researchers from Dartmouth Medical School in New ...
(Date:11/21/2008)...ate University College of Medicine research team l...w layer of regulation in the cell division cycle, ... way cancer begins. , Wang, an assistant profess...ne, said the findings will lead to an improved abi...gn of new drugs that kill cancer cells by inhibiti...
(Date:11/21/2008)...FirstCall/ -- Heska Corporation,(Nasdaq: HSKA )...ociety of,Security Analysts, 12th Annual Biotech ...08 at 1177 Avenue of the Americas, 2nd Floor in Ne...n at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain T...r two weeks,following the presentation through a ...
(Date:11/21/2008)... future antibiotic resistance from widespread use ...- People with moderate to severe chronic obstructi...the frequency of exacerbations through a regular, .... , The study, published in the first issue fo... and Critical Care Medicine , found that twice-dai...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...aimed to prevent more sudden deaths than defibrill... defibrillators according to US scientists.// Rese...mpared such preventive strategies by food suppleme... computer-simulated community of 100,000 people th...
...and why some people are hairier than others may ha...s.// The molecular mechanisms that determine whic...es, deciding the body's hair pattern has been disc...niversity of Manchester. This study on mice will ...
...wo-thirds of the people in the US do not wash thei...t had been newly formed had conducted the survey o... that the participants had been chosen from around..., United Arab Emirates, India, Malaysia, and South...
...n commissioned by the Australian government states... might be an cost effective option to control// th...rt also stated that to have found the various prog...ive, but raised questions about the effectiveness ...
Other Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2
(Date:11/20/2008)...alif., Nov. 20 Bionovo, ... present results from the Phase 1B,clinical trial...tic breast,cancer, BZL101, at the Society for Int...e in Atlanta, Georgia. The Company,s oral present...will be presented as a part of the Best of the,SI...
(Date:11/20/2008)...20 PAREXEL International...iopharmaceutical services provider, today announce...ovide regulatory consulting and clinical research ..., PAREXEL now has locations throughout five import...ich also include Argentina, Brazil, Chile, and Mex...
(Date:11/19/2008)...tudy did not achieve statistical significance , ...l/ -- Pharmos Corporation (Nasdaq: PARS ) today ... of its topical NanoEmulsion (NE) drug delivery te...ine. , , The multi-center, randomized, doub... safety and efficacy of the Company,s 3% Diclofena...
(Date:11/19/2008)...Million Payment from Roche- , , MONTVALE, N...maceuticals Corp. (Nasdaq: MEMY ) today announce... Phase 2 trial of R3487/MEM 3454, its lead alpha-7...nt associated with schizophrenia (CIAS). The Comp...al, triggering a $5.0 million payment from its par...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Almost Family Reports Third Quarter 2008 Results 28817 1Almost Family Reports Third Quarter 2008 Results 28817 2Almost Family Reports Third Quarter 2008 Results 28817 3Almost Family Reports Third Quarter 2008 Results 28817 4Almost Family Reports Third Quarter 2008 Results 28817 5Almost Family Reports Third Quarter 2008 Results 28817 6Almost Family Reports Third Quarter 2008 Results 28817 7Almost Family Reports Third Quarter 2008 Results 28817 8Almost Family Reports Third Quarter 2008 Results 28817 9Almost Family Reports Third Quarter 2008 Results 28817 10Almost Family Reports Third Quarter 2008 Results 28817 11Almost Family Reports Third Quarter 2008 Results 28817 12Almost Family Reports Third Quarter 2008 Results 28817 13Almost Family Reports Third Quarter 2008 Results 28817 14Almost Family Reports Third Quarter 2008 Results 28817 15Almost Family Reports Third Quarter 2008 Results 28817 16InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 1InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 2InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 3InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 4InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 5InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 6InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 7InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 8InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 9InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 10InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 11Neurobiological Technologies to Present at the Rodman 26 Renshaw 10th Annual Healthcare Conference in New York on November 10 8897 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 6
...E)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasdaq:G... III,AIR-CF2 study evaluating aztreonam lysine for...c fibrosis (CF) who have,pulmonary Pseudomonas aer...eatment course of aztreonam lysine significantly i...s (IV) antibiotics versus,placebo. All patients re...
... WIRE)--Apr 23, 2007 - CytRx Corporation,(NASDAQ:C...Ai),delivery technology exclusively licensed to it...orporation (RXi), has been,published in the April ... Chemical Biology. The technology was developed by...and University of,Massachusetts Medical School (UM...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4